Bulletin from annual general meeting in Sedana Medical AB (publ)
Sedana Medical AB (publ) held the annual general meeting on 22 May 2018 in Stockholm. Below follows a summary of the resolutions that were made during the meeting.
Adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet
The meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated profit and loss statement and consolidated balance sheet included in the annual report.
The meeting resolved that the company’s accumulated profits should be carried forward in new account and that no dividend was to be paid for the previous financial year.
The meeting resolved to discharge the board members and the managing director from liability for the previous financial year.
Determination of the fees payable to the members of the board of directors and the auditors
The general meeting resolved that fees payable to the board of directors for the period until the end of the next annual general meeting shall amount to SEK 525,000 in total of which SEK 225,000 to the chairman, SEK 50,000 to each of suggested board members Sten Gibeck, Bengt Julander, Ola Magnusson and Michael Ryan and SEK 100,000 to the suggested board member Eva Walde.
Election of board members and auditor
The meeting resolved to re-elect Thomas Eklund, Sten Gibeck, Bengt Julander, Ola Magnusson and Michael Ryan and to newly-elect Eva Walde as ordinary board members until the end of the next annual general meeting. The meeting also resolved to re-elect Thomas Eklund as chairman of the board of directors until the end of the next annual general meeting.
The auditing firm R3 KB was re-elected as auditor of the company for the period until the end of the next annual general meeting.
Resolution on principles for the appointment of the nomination committee and instructions for the nomination committee
The meeting resolved to adopt principles for the appointment of the nomination committee and instructions for the nomination committee in accordance with the nomination committee’s proposal.
Resolution on authorization for the board to resolve on new issue of shares
The meeting resolved to authorizes the board to resolve, on one or more occasions prior to the next annual general meeting, with or without prejudice to shareholders’ preferential rights, on new issues of shares which, in aggregate, does not exceed 15 percent of the total number of outstanding shares after use of the authorization. A new issue may be issued with or without requirements regarding the amount, offsetting or other conditions referred to in Chapter 13, Section 5, first paragraph, 6 of the Swedish Companies Act. The purpose of the authorization is to give the board flexibility in the work to ensure that the company can be appropriately allocated capital for the financing of the business, business or product acquisition, and to enable the company’s ownership base to be broadened.
For additional information, please contact:
Christer Ahlberg, CEO, Sedana Medical AB
+46 70 675 33 30
Maria Engström, CFO, Sedana Medical AB
+46 70 674 33 30
Thomas Eklund, Chairman of the board, Sedana Medical AB
+46 70 824 20 25
Sedana Medical is listed on Nasdaq First North in Stockholm
and Erik Penser Bank (+46 8 463 83 00) is certified adviser to Sedana Medical.
This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the Nasdaq First North Rulebook. The information was released for public disclosure, through the agency of the contact persons above, on 22 May 2018 at 6.00 p.m. (CET).
Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane) Sedana Medical has direct sales in the Nordic countries, Germany, France and Spain as well as external distributors in the rest of Europe, Middle East, Canada, Australia and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.